1. Home
  2. Research
  3. Centers & Labs
  4. RIKEN BioResource Research Center

RIKEN BioResource Research Center iPSC-based Drug Discovery and Development Team

Team Leader: Haruhisa Inoue (M.D., Ph.D.)

Research Summary

Haruhisa  Inoue(M.D., Ph.D.)

At RIKEN BRC, disease-specific iPS cells established from patients with various diseases are provided as bioresources. The disease-specific iPS cells are used for drug discovery and development.

Three missions of the team are as follows.

  • Using iPS cells of RIKEN BRC to develop infrastructure technology for drug discovery and development
  • Innovating the technology that will open an avenue for practical and general uses
  • Bridging disease-specific iPS cells and academia / industry in the field of translational research

Main Research Fields

  • Medicine, Dentistry & Pharmacy

Related Research Fields

  • Biology

Keywords

  • Disease modeling
  • Drug discovery and development
  • Disease-specific iPS cells

Selected Publications

Papers with an asterisk(*) are based on research conducted outside of RIKEN.

  • 1.*Nakazeki F, Tsuge I, Horie T, Imamura K, Tsukita K, Hotta A, Baba O, Kuwabara Y, Nishino T, Nakao T, Nishiga M, Nishi H, Nakashima Y, Ide Y, Koyama S, Kimura M, Tsuji S, Naitoh M, Suzuki S, Izumi Y, Kawarai T, Kaji R, Kimura T, Inoue H, Ono K.:
    "MiR-33a is a therapeutic target in SPG4-related hereditary spastic paraplegia human neurons."
    Clinical Science CS20180980; doi:10.1042/CS20180980, (2019)
  • 2.Suga M, Kondo T, Imamura K, Shibukawa R, Okanishia Y, Sagara Y, Tsukita K, Enami T, Furujo M, Saijo K, Nakamura Y, Osawa M, Saito MK, Yamanaka S, Inoue H.:
    "Generation of a human induced pluripotent stem cell line, BRCi001-A, derived from a patient with mucopolysaccharidosis type I."
    Stem Cell Research, 101406, doi:10.1016/j.scr.2019.101406, (2019)
  • 3.*Karagiannis P, Takahashi K, Saito M, Yoshida Y, Okita K, Watanabe A, Inoue H, Yamashita JK, Todani M, Nakagawa M, Osawa M, Yashiro Y, Yamanaka S, Osafune K.:
    "Induced Pluripotent Stem Cells and Their Use in Human Models of Disease and Development."
    Physiological Reviews, 1;99(1):79-114, (2019)
  • 4.Niki T, Imamura K, Enami T, Kinoshita M, Inoue H.:
    "Establishment of human induced pluripotent stem cell line from a patient with Angelman syndrome carrying the deletion of maternal chromosome"
    15q11.2-q13. Stem Cell Research 34(2019) 101363, doi: 10.1016/j.scr.2018.101363, (2018)
  • 5.*Tsuburaya N, Homma K, Higuchi T, Balia A, Yamakoshi H, Shibata N, Nakamura S, Nakagawa H, Ikeda SI, Umezawa N, Kato N, Yokoshima S, Shibuya M, Shimonishi M, Kojima H, Okabe T, Nagano T, Naguro I, Imamura K, Inoue H, Fujisawa T, Ichijo H.:
    "A small-molecule inhibitor of SOD1-Derlin-1 interaction ameliorates pathology in an ALS mouse model."
    Nat Commun, 10;9(1):2668 (2018)
  • 6.*Kondo T, Imamura K, Funayama M, Tsukita K, Miyake M, Ohta A, Woltjen K, Nakagawa M, Asada T, Arai T, Kawakatsu S, Izumi Y, Kaji R, Iwata N, Inoue H.:
    "iPSC-Based Compound Screening and In Vitro Trials Identify a Synergistic Anti-amyloid β Combination for Alzheimer's Disease."
    Cell Reports 21(8), 2304-2312(2017)
  • 7.*Nakano-Kobayashi A, Awaya T, Kii I, Sumida Y, Okuno Y, Yoshida S, Sumida T, Inoue H, Hosoya T, Hagiwara M.:
    "Prenatal neurogenesis induction therapy normalizes brain structure and function in Down syndrome mice."
    Proceedings of the National Academy of Sciences 114(38), 10268-10273(2017)
  • 8.Sekine S, Kondo T, Murakami N, Imamura K, Enami T, Shibukawa R, Tsukita K, Funayama M, Inden M, Kurita H, Hozumi I, Inoue H.:
    "Induced pluripotent stem cells derived from a patient with familial idiopathic basal ganglia calcification (IBGC) caused by a variant in SLC20A2 gene."
    Stem Cell Research, 24, 40-43 (2017)
  • 9.Murakamia N, Ishikawa T, Kondo T, Imamura K, Tsukita K, Enami T, Funayama M, Shibukawa R, Matsumoto S, Izumi Y, Ohta E, Obata F, Kaji R, Inoue H.:
    "Establishment of DYT5 patient-specific induced pluripotent stem cells with a GCH1 mutation."
    Stem Cell Research, 24, 36-39 (2017)
  • 10.Tan G W, Kondo T, Murakamia N, Imamura K, Enami T, Tsukita K, Shibukawa R, Funayama M, Matsumoto R, Ikeda A, Takahashi R, Inoue H.:
    "Induced pluripotent stem cells derived from an autosomal dominant lateral temporal epilepsy (ADLTE) patient carrying S473L mutation in leucine-rich glioma inactivated 1 (LGI1)."
    Stem Cell Research, 24, 12-15 (2017)

Events

Publications

  • Haruhisa Inoue, Yukio Nakamura (Editors):
    "Medical Applications of iPS Cells - Inovation in Medical Sciences" Springer, (2019)

Related Links

Lab Members

Principal investigator

Haruhisa Inoue
Team Leader

Core members

Mika Suga
Research & Development Scientist
Yuichiro Yada
Postdoctoral Researcher
Ran Shibukawa
Technical Staff II
Yukako Sagara
Technical Staff II
Yasue Okanishi
Technical Staff II

Contact Information

Laboratory Wing 7F, Keihanna Plaza (Keihanna Science City)
1-7 Hikaridai, Seika-cho, Soraku-gun, Kyoto 619-0237, Japan
Email: Inoue-brc [at] ml.riken.jp

Top